Zhu Jianqin, Zhu Weijin, Zhou Xulin, Hua Jingwen, Sun Xiaochun
School of Medicine, Jiangsu University, Zhenjiang, Jiangsu, China.
Changzhou Hospital of Traditional Chinese Medicine, Changzhou, Jiangsu, China.
Curr Cancer Drug Targets. 2025 Jun 18. doi: 10.2174/0115680096376016250607151653.
The initiation and progression of breast cancer generally involve complex immune regulatory mechanisms, with increased expression of programmed cell death ligand 1 (PD-L1) as an essential factor for immune evasion and the formation of a tumor-promoting immune microenvironment. Emerging evidence underscores the regulatory role of non-coding RNAs (ncRNAs) in modulating PD-L1 expression, influencing immune evasion, tumorigenesis, and therapy resistance in breast cancer. Therefore, it is crucial further to clarify alternative regula-tory mechanisms that control PD-L1 expression. The variations in PD-L1 expression among different breast cancer subtypes and the mechanisms by which ncRNAs regulate the expres-sion of PD-L1 are delineated. This study explores the potential and challenges of combining ncRNA-based therapy with PD-L1 inhibitors, offering insights into PD-L1 regulation and per-sonalized treatment strategies in breast cancer.
乳腺癌的发生和发展通常涉及复杂的免疫调节机制，程序性细胞死亡配体1（PD-L1）表达增加是免疫逃逸和形成促肿瘤免疫微环境的关键因素。新出现的证据强调了非编码RNA（ncRNA）在调节PD-L1表达、影响乳腺癌免疫逃逸、肿瘤发生和治疗耐药性方面的调节作用。因此，进一步阐明控制PD-L1表达的替代调节机制至关重要。本文阐述了不同乳腺癌亚型中PD-L1表达的差异以及ncRNA调节PD-L1表达的机制。本研究探索了基于ncRNA的治疗与PD-L1抑制剂联合应用的潜力和挑战，为乳腺癌中PD-L1的调节和个性化治疗策略提供了见解。
